Atossa Genetics (NASDAQ:ATOS) Shares Pass Above 200 Day Moving Average of $0.00
Atossa Genetics Inc (NASDAQ:ATOS) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.00 and traded as high as $2.06. Atossa Genetics shares last traded at $2.03, with a volume of 749 shares.
A number of research analysts recently commented on the company. Maxim Group reissued a “hold” rating on shares of National Beverage in a report on Thursday, June 27th. ValuEngine raised Zogenix from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 27th.
The business has a fifty day moving average of $2.21. The firm has a market capitalization of $18.75 million, a P/E ratio of -0.37 and a beta of 3.31.
A hedge fund recently bought a new stake in Atossa Genetics stock. Barclays PLC acquired a new position in shares of Atossa Genetics Inc (NASDAQ:ATOS) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 32,384 shares of the company’s stock, valued at approximately $33,000. Barclays PLC owned approximately 0.57% of Atossa Genetics at the end of the most recent reporting period. Institutional investors and hedge funds own 3.18% of the company’s stock.
About Atossa Genetics (NASDAQ:ATOS)
Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.
Further Reading: Why does a company issue an IPO?
Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.